Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
BIIB

BIIB - Biogen Inc Stock Price, Fair Value and News

230.63USD+0.59 (+0.26%)Delayed

Market Summary

BIIB
USD230.63+0.59
Delayed
0.26%

BIIB Stock Price

View Fullscreen

BIIB RSI Chart

BIIB Valuation

Market Cap

33.6B

Price/Earnings (Trailing)

28.78

Price/Sales (Trailing)

3.47

EV/EBITDA

18.41

Price/Free Cashflow

24.18

BIIB Price/Sales (Trailing)

BIIB Profitability

Operating Margin

94.35%

EBT Margin

13.69%

Return on Equity

7.67%

Return on Assets

4.39%

Free Cashflow Yield

4.14%

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

9.7B

Rev. Growth (Yr)

-7%

Rev. Growth (Qtr)

-4.01%

BIIB Earnings

Earnings (TTM)

1.2B

Earnings Growth (Yr)

1.42%

Earnings Growth (Qtr)

57.55%

Breaking Down BIIB Revenue

Last 7 days

4.1%

Last 30 days

20.0%

Last 90 days

5.3%

Trailing 12 Months

-24.5%

How does BIIB drawdown profile look like?

BIIB Financial Health

Current Ratio

2.1

Debt/Equity

0.41

Debt/Cashflow

0.26

BIIB Investor Care

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

8.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.7B000
202310.1B10.0B10.0B9.8B
202210.8B10.6B10.4B10.2B
202112.6B11.7B11.1B11.0B
202014.4B14.5B14.3B13.4B
201913.8B14.1B14.2B14.4B
201812.6B12.9B13.2B13.5B
201711.5B11.7B11.8B12.3B
201610.9B11.2B11.4B11.4B
201510.1B10.3B10.6B10.8B
20147.6B8.3B9.0B9.7B
20135.6B5.9B6.4B6.9B
20125.1B5.3B5.4B5.5B
20114.8B4.8B4.9B5.0B
20104.4B4.6B4.6B4.7B
20094.2B4.3B4.3B4.4B
200803.5B3.8B4.1B
20070003.2B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Biogen Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 01, 2024
keeney adam
sold (taxes)
-59,651
216
-276
head of corporate development
May 01, 2024
keeney adam
acquired
-
-
938
head of corporate development
Apr 02, 2024
singhal priya
sold
-19,817
213
-93.00
head of development
Apr 01, 2024
murphy nicole
acquired
-
-
240
head of pharm ops and tech
Apr 01, 2024
murphy nicole
sold (taxes)
-25,135
214
-117
head of pharm ops and tech
Feb 22, 2024
singhal priya
sold
-57,962
221
-262
head of development
Feb 16, 2024
gregory ginger
acquired
-
-
4,704
evp, human resources
Feb 16, 2024
alexander susan h
acquired
-
-
5,037
evp chief legal officer
Feb 16, 2024
murphy nicole
sold (taxes)
-133,639
219
-610
head of pharm ops and tech
Feb 16, 2024
izzar rachid
acquired
-
-
2,017
head of global product strat.

1–10 of 50

Which funds bought or sold BIIB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
FSA Wealth Management LLC
unchanged
-
-14,823
74,177
0.03%
May 16, 2024
Brown Shipley& Co Ltd
reduced
-54.75
-35,736
21,452
0.01%
May 16, 2024
Garner Asset Management Corp
sold off
-100
-5,233
-
-%
May 16, 2024
Tidal Investments LLC
added
99.08
874,866
2,202,100
0.04%
May 16, 2024
HANCOCK WHITNEY CORP
added
5.92
-61,569
462,959
0.02%
May 16, 2024
Global Financial Private Client, LLC
unchanged
-
-3,954
19,335
0.01%
May 16, 2024
Pineridge Advisors LLC
sold off
-100
-16,820
-
-%
May 16, 2024
COMERICA BANK
added
2.94
-1,512,010
9,124,460
0.04%
May 16, 2024
Ancora Advisors LLC
reduced
-66.8
-45,114
17,250
-%
May 16, 2024
Motley Fool Asset Management LLC
added
8.06
-102,221
924,837
0.06%

1–10 of 39

Are Funds Buying or Selling BIIB?

Are funds buying BIIB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BIIB
No. of Funds

Unveiling Biogen Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 12, 2024
primecap management co/ca/
11.22%
16,264,481
SC 13G/A
Feb 12, 2024
vanguard group inc
10.02%
14,521,342
SC 13G/A
Feb 12, 2024
vanguard group inc
9.94%
14,406,879
SC 13G/A
Jan 24, 2024
blackrock inc.
9.8%
14,246,320
SC 13G/A
Feb 09, 2023
primecap management co/ca/
10.9%
15,700,576
SC 13G/A
Feb 09, 2023
vanguard group inc
8.32%
11,976,623
SC 13G/A
Jan 24, 2023
blackrock inc.
9.9%
14,260,137
SC 13G/A
Mar 07, 2022
blackrock inc.
9.4%
13,736,954
SC 13G/A
Feb 10, 2022
primecap management co/ca/
10.73%
15,757,405
SC 13G/A
Feb 09, 2022
vanguard group inc
7.85%
11,537,299
SC 13G/A

Recent SEC filings of Biogen Inc

View All Filings
Date Filed Form Type Document
May 03, 2024
4
Insider Trading
Apr 26, 2024
ARS
ARS
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
DEFA14A
DEFA14A
Apr 24, 2024
10-Q
Quarterly Report
Apr 24, 2024
8-K
Current Report
Apr 12, 2024
PRE 14A
PRE 14A
Apr 03, 2024
4
Insider Trading
Apr 03, 2024
4
Insider Trading
Apr 02, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Biogen Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
372.2B
85.6B
6.82% -1.69%
9.67
4.35
5.68% 202.39%
332.3B
61.4B
4.65% 15.09%
144.1
5.41
6.11% -82.30%
167.7B
29.5B
18.35% 39.38%
44.55
5.68
12.76% -52.47%
162.3B
57.8B
12.71% -21.46%
129.52
2.81
76.51% -86.81%
84.4B
27.4B
1.23% -13.37%
174.21
3.07
1.51% -91.32%
18.4B
16.0B
23.52% 97.09%
-37.29
1.15
7.23% 71.10%
MID-CAP
4.1B
1.7B
0.67% -19.91%
9.41
2.37
54.01% 364.56%
4.1B
4.6B
-0.70% -10.77%
-528.11
0.89
-0.06% 94.55%
2.5B
9.0B
-21.94% -21.03%
-5.45
0.28
10.01% -27.45%
2.1B
676.2M
8.56% -0.82%
13.75
3.14
30.38% 66.04%
SMALL-CAP
1.5B
743.2M
15.12% -18.85%
-4.35
2.06
24.65% 80.36%
25.8M
1.3M
18.52% -47.17%
-3.49
19.84
-98.14% -104.71%
18.4M
89.6M
6.93% 25.60%
-1.29
0.19
287.27% -129.41%
2.5M
21.5M
2.70% -90.89%
-0.32
0.12
66.16% 61.83%
633.5K
115.7M
-50.00% -97.38%
0
0.01
-2.22% -352.48%

Biogen Inc News

Latest updates
Defense World83 minutes ago
Yahoo New Zealand News26 hours ago
Seeking Alpha16 May 202401:00 pm
Yahoo Singapore News14 May 202410:08 pm
Yahoo Finance22 Apr 202407:00 am

Biogen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-4.0%2,2912,3862,5302,4562,4632,5442,5092,5892,5322,7342,7792,7752,6942,8533,3763,6823,5343,6713,6003,6173,490
Costs and Expenses-12.8%1,8262,0952,6721,7482,0251,9401,1371,3202,1842,5822,4882,1931,7202,6862,2901,7071,7141,8941,7941,6611,987
  S&GA Expenses-4.4%582609788548605633563573635788654637595806573555570665555588568
EBITDA Margin5.2%0.22*0.21*0.23*0.38*0.44*0.43*0.40*0.29*0.22*0.23*0.21*0.26*---------
Interest Expenses-3.2%69.0072.0064.0049.0063.0055.0060.0066.0066.0066.0066.0056.0065.0056.0056.0066.0044.0046.0046.0048.0048.00
Income Taxes67.2%71.0043.00-72.9011551.0054.00236217126443-25.90-40944.0013.00241446292276211248423
Earnings Before Taxes59.4%465292-1417084386041,3711,2703474052915824673539582,0381,6991,7281,7791,7591,860
EBT Margin3.9%0.14*0.13*0.16*0.31*0.36*0.35*0.33*0.22*0.15*0.16*0.15*0.20*---------
Net Income57.5%393250-68.105923885501,1351,0583043683294494103587021,5421,3991,4401,5461,4941,409
Net Income Margin2.3%0.12*0.12*0.15*0.27*0.31*0.30*0.28*0.19*0.13*0.14*0.14*0.16*---------
Free Cashflow1062.6%507-52.70518416389-2616027001047877631,155---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.0%26,56826,84528,19325,15724,59824,55424,85425,08123,61423,87723,80724,47023,85524,61924,93425,51226,11927,23427,48426,28826,446
  Current Assets-1.5%6,7566,8598,45410,4329,7639,7919,7669,7417,9167,8577,1627,1846,7206,8877,8438,4948,0078,3828,4487,9108,943
    Cash Equivalents2.3%1,0741,0502,2882,6182,8983,4193,6762,6471,7492,2611,5421,7421,2181,3312,2252,3852,5912,9142,3441,7232,243
  Inventory-0.4%2,5172,5272,9821,3341,2811,3441,3751,2941,2151,3521,3481,2551,1721,0691,028953859804752777770
  Net PPE-1.0%3,2753,3103,3023,3073,3013,2993,2663,3553,3733,4163,4113,4423,4383,4123,3603,3313,2823,2473,1383,0783,014
  Goodwill0.1%6,2276,2194745,7545,7525,7495,7415,7505,7585,7615,7615,7645,7635,7625,7565,7515,7525,7585,7465,7495,640
Liabilities-5.7%11,35512,04513,71410,69610,81111,16612,08713,21812,39412,91812,92513,25613,19213,93314,19014,22313,58213,89513,49213,33912,624
  Current Liabilities-6.2%3,2233,4345,0223,1873,0153,2733,9265,0183,9474,2984,2123,3473,1663,7423,8043,4474,6394,8644,4323,2113,149
  Long Term Debt-7.3%6,2906,7886,7866,2856,2836,2816,2796,2776,2766,2746,2727,2697,2677,4267,4257,4244,4604,4594,4585,9495,943
Shareholder's Equity2.8%15,21314,79914,48414,46113,78713,38812,76711,86311,22110,96010,88211,21510,66310,68610,74511,28912,53713,33913,99212,94913,822
  Retained Earnings2.2%18,02117,62817,37817,44616,85416,46715,91614,96014,21613,91213,54413,90113,83413,97613,96114,46715,67316,45517,06516,18317,027
  Additional Paid-In Capital8.9%33030324217191.0073.00--11968.00------0.00----
Shares Outstanding0.2%145145145145144144146146147147148150---------
Minority Interest----4.10-6.40-9.60-9.50-8.70-9.10-21.6064.00452463-19.00-14.20-14.00-19.50-10.00-4.10-4.10-4.10-7.90
Float----41,191---29,398---51,265---42,103---43,010-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations4325.6%55313.00592487455-1756617371628388051,227769-3671,1811,9491,4671,9601,6951,9641,460
  Share Based Compensation-61.9%73.00191-64.80-74.1076.00189-65.70-58.0068.00170-57.60-55.8070.00132-35.40-49.5068.00139-47.80-55.0046.00
Cashflow From Investing89.9%-66.00-652-1,742-753-953-1411,672694-648-112-233-152-64.70-166-52.40-832443708-365-110239
Cashflow From Financing32.0%-439-646849-9.80-43.40-7.40-1,251-471-16.5010.00-746-564-785-401-1,312-1,313-2,245-2,116-689-2,375-679
  Buy Backs-------250500--7504506004001,2502,8092,2202,0937182,402656
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BIIB Income Statement

2024-03-31
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenue$ 2,290.5$ 2,463.0
Cost and expenses:  
Cost of sales, excluding amortization and impairment of acquired intangible assets542.2662.8
Research and development452.9570.6
Selling, general and administrative581.5605.0
Amortization and impairment of acquired intangible assets78.350.2
Collaboration profit sharing/(loss reimbursement)65.657.1
Restructuring charges11.59.6
Other (income) expense, net93.769.4
Total cost and expense1,825.72,024.7
Income before income tax (benefit) expense464.8438.3
Income tax (benefit) expense71.450.7
Net income393.4387.6
Net income (loss) attributable to noncontrolling interests, net of tax0.0(0.3)
Net income attributable to Biogen Inc.$ 393.4$ 387.9
Net income per share:  
Basic earnings per share attributable to Biogen Inc.$ 2.71$ 2.69
Diluted earnings per share attributable to Biogen Inc.$ 2.70$ 2.67
Weighted-average shares used in calculating:  
Basic earnings per share attributable to Biogen Inc.145.2144.4
Diluted earnings per share attributable to Biogen Inc.145.9145.2
Product, net  
Total revenue$ 1,711.9$ 1,763.3
Revenue from anti-CD20 therapeutic programs  
Total revenue394.0399.5
Contract manufacturing, royalty and other revenue  
Total revenue$ 184.6$ 300.2

BIIB Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 1,074.4$ 1,049.9
Inventory2,516.82,527.4
Other current assets1,165.31,182.0
Total current assets6,756.26,859.3
Property, plant and equipment, net3,275.33,309.7
Operating lease assets428.1420.0
Intangible assets, net8,284.78,363.0
Goodwill6,227.46,219.2
Deferred tax asset898.3928.6
Investments and other assets697.6745.0
Total assets26,567.626,844.8
Current liabilities:  
Current portion of term loan250.0150.0
Taxes payable231.2257.4
Accounts payable387.0403.3
Accrued expense and other2,354.62,623.6
Total current liabilities3,222.83,434.3
Notes payable and term loan6,290.16,788.2
Deferred tax liability658.1641.8
Long-term operating lease liabilities406.5400.0
Other long-term liabilities777.1781.1
Total liabilities11,354.612,045.4
Commitments, contingencies and guarantees
Biogen Inc. shareholders’ equity:  
Preferred stock, par value $0.000 per share0.00.0
Common stock, par value $— per share0.10.1
Additional paid-in capital329.5302.5
Accumulated other comprehensive income (loss)(160.5)(153.7)
Retained earnings18,021.017,627.6
Treasury stock, at cost(2,977.1)(2,977.1)
Total equity15,213.014,799.4
Total liabilities and equity26,567.626,844.8
Nonrelated Party  
Current assets:  
Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively1,604.51,664.1
Related Party  
Current assets:  
Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively$ 395.2$ 435.9
BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEbiogen.com
 INDUSTRYPharmaceuticals
 EMPLOYEES8725

Biogen Inc Frequently Asked Questions


What is the ticker symbol for Biogen Inc? What does BIIB stand for in stocks?

BIIB is the stock ticker symbol of Biogen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biogen Inc (BIIB)?

As of Fri May 17 2024, market cap of Biogen Inc is 33.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers. The fair value of Biogen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biogen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIIB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biogen Inc a good stock to buy?

The fair value guage provides a quick view whether BIIB is over valued or under valued. Whether Biogen Inc is cheap or expensive depends on the assumptions which impact Biogen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIIB.

What is Biogen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BIIB's PE ratio (Price to Earnings) is 28.78 and Price to Sales (PS) ratio is 3.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIIB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biogen Inc's stock?

In the past 10 years, Biogen Inc has provided -0.014 (multiply by 100 for percentage) rate of return.